Trial · NCT00953927
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| To Evaluate the Safety Profile of MVA85A/AERAS-485 in Bacillus Calmette-Guerin (BCG) -Vaccinated, HIV-negative Infants. | Investigational Vaccine | 95.9 | 95% Confidence Interval 94.7 to 96.8 | percentage of all subjects vaccinated | |
| To Evaluate the Safety Profile of MVA85A/AERAS-485 in Bacillus Calmette-Guerin (BCG) -Vaccinated, HIV-negative Infants. | Control Group | 83.7 | 95% Confidence Interval 81.7 to 85.6 | percentage of all subjects vaccinated | |
| To Evaluate the Efficacy of the MVA85A/AERAS-485 Vaccine Compared to Controls in Prevention of Tuberculosis Using an Endpoint Derived From Epidemiological Cohort Surveys in BCG Vaccinated Infants. | Investigational Vaccine | 32 | participants with a diagnosis of TB | ||
| To Evaluate the Efficacy of the MVA85A/AERAS-485 Vaccine Compared to Controls in Prevention of Tuberculosis Using an Endpoint Derived From Epidemiological Cohort Surveys in BCG Vaccinated Infants. | Control Group | 39 | participants with a diagnosis of TB | ||
| To Evaluate the Immunogenicity of the MVA85A/AERAS-485 Vaccine Compared to Controls as Described by Flow Cytometric Intracellular Cytokine Staining of CD4 and CD8 T Cells. | Investigational Vaccine | Percent cytokine expressing CD4 cells | 0.012 | 95% Confidence Interval 0.003 to 0.038 | percentage of cytokine expressing cells |
| To Evaluate the Immunogenicity of the MVA85A/AERAS-485 Vaccine Compared to Controls as Described by Flow Cytometric Intracellular Cytokine Staining of CD4 and CD8 T Cells. | Control Group | Percent cytokine expressing CD4 cells | 0.003 | 95% Confidence Interval 0.000 to 0.011 | percentage of cytokine expressing cells |
| To Evaluate the Immunogenicity of the MVA85A/AERAS-485 Vaccine Compared to Controls as Described by Flow Cytometric Intracellular Cytokine Staining of CD4 and CD8 T Cells. | Investigational Vaccine | Percent cytokine expressing CD8 cells | 0.007 | 95% Confidence Interval 0.000 to 0.011 | percentage of cytokine expressing cells |
| To Evaluate the Immunogenicity of the MVA85A/AERAS-485 Vaccine Compared to Controls as Described by Flow Cytometric Intracellular Cytokine Staining of CD4 and CD8 T Cells. | Control Group | Percent cytokine expressing CD8 cells | 0.000 | 95% Confidence Interval 0.000 to 0.010 | percentage of cytokine expressing cells |
| To Evaluate the Immunogenicity of the MVA85A/AERAS-485 Vaccine Compared to Controls as Described by the ex Vivo Enzyme Linked Immunospot (ELISPOT) Test Used in Previous MVA85A/AERAS-485 Human Trials. | Investigational Vaccine | 143.000 | 95% Confidence Interval 107.000 to 295.350 | SFC per million PBMCs | |
| To Evaluate the Immunogenicity of the MVA85A/AERAS-485 Vaccine Compared to Controls as Described by the ex Vivo Enzyme Linked Immunospot (ELISPOT) Test Used in Previous MVA85A/AERAS-485 Human Trials. | Control Group | 1.000 | 95% Confidence Interval 0.000 to 2.000 | SFC per million PBMCs | |
| To Evaluate the Immunogenicity of the MVA85A/AERAS-485 Vaccine Compared to Controls as Described by the University of Capetown (UCT) Whole Blood Intracellular Cytokine Assay. | Investigational Vaccine | Percent IL2/IFN-gamma/TNF expressing CD4 cells | 0.030 | 95% Confidence Interval 0.022 to 0.079 | percentage of cytokine expressing cells |
| To Evaluate the Immunogenicity of the MVA85A/AERAS-485 Vaccine Compared to Controls as Described by the University of Capetown (UCT) Whole Blood Intracellular Cytokine Assay. | Control Group | Percent IL2/IFN-gamma/TNF expressing CD4 cells | 0.001 | 95% Confidence Interval 0.000 to 0.001 | percentage of cytokine expressing cells |
| To Evaluate the Immunogenicity of the MVA85A/AERAS-485 Vaccine Compared to Controls as Described by the University of Capetown (UCT) Whole Blood Intracellular Cytokine Assay. | Investigational Vaccine | Percent IL2/IFN-gamma/ TNF expressing CD8 cells | 0.000 | 95% Confidence Interval 0.000 to 0.000 | percentage of cytokine expressing cells |
| To Evaluate the Immunogenicity of the MVA85A/AERAS-485 Vaccine Compared to Controls as Described by the University of Capetown (UCT) Whole Blood Intracellular Cytokine Assay. | Control Group | Percent IL2/IFN-gamma/ TNF expressing CD8 cells | 0.000 | 95% Confidence Interval 0.000 to 0.000 | percentage of cytokine expressing cells |
| To Evaluate the QuantiFERON Conversion Rate at Final Study Assessment in MVA85A/AERAS-485 Recipients Compared to Controls in Infants Without a Diagnosis of Tuberculosis During the Trial. | Investigational Vaccine | 178 | participants | ||
| To Evaluate the QuantiFERON Conversion Rate at Final Study Assessment in MVA85A/AERAS-485 Recipients Compared to Controls in Infants Without a Diagnosis of Tuberculosis During the Trial. | Control Group | 171 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00953927/results